bioAffinity Technologies
BIAF
20 hedge funds and large institutions have $783K invested in bioAffinity Technologies in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
1,026% more capital inflows, than outflows
Capital inflows: $1.21M | Capital outflows: $108K
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
54% more funds holding
Funds holding: 13 → 20 (+7)
11.61% more ownership
Funds ownership: 5.39% → 16.99% (+12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$747K |
| 2 |
BlackRock
New York
|
+$202K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54.9K |
| 4 |
Jane Street
New York
|
+$54.7K |
| 5 |
HRT Financial
New York
|
+$42.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schonfeld Strategic Advisors
New York
|
-$93.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.2K |
| 3 |
Ameritas Advisory Services
Lincoln,
Nebraska
|
-$3.83K |
| 4 |
Citigroup
New York
|
-$218 |
| 5 |
Caitong International Asset Management
Hong Kong
|
-$4 |
BIAF Hedge Fund Activity: Q2 2026 in Review
20 of the 8,372 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q2 2026, worth a combined $783K — down 16% from $929K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BIAF positions and 3 closed out — a net gain of 7 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $747K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $93.5K sold.
- 20 institutional investors held bioAffinity Technologies (BIAF) as of Q2 2026, up from 13 in Q1 2026.
- Funds reported $783K of bioAffinity Technologies stock for Q2 2026, down 16% quarter-over-quarter.
- 10 funds opened new bioAffinity Technologies positions in Q2 2026 and 3 closed out, a net change of +7 holders.
- The largest bioAffinity Technologies buyer in Q2 2026 was Sabby Management, an estimated $747K added.
- The largest bioAffinity Technologies seller in Q2 2026 was Schonfeld Strategic Advisors, an estimated $93.5K sold.
Based on aggregated 13F filings for Q2 2026.